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Importance Some studies have observed that men with liver cirrhosis have lower serum 
prostate specific antigen (PSA) concentration, which could delay the detection of an occult 
prostate cancer. Yet, no previous study has examined the association of liver function and 
advanced fibrosis with serum PSA level in a US nationally representative sample of men. 
Objective To evaluate the association of liver fibrosis scores with PSA level among men 
aged older than 40 years in the overall US population and among non-Hispanic White, non-
Hispanic Black, and Mexican-American or other Hispanic men.  
Design, Setting and Participants Data from the 2001 to 2010 continuous National Health 
and Nutrition Examination Survey (NHANES) were used. Males aged 40 years and over 
without a diagnosis of prostate cancer and who had serum PSA, liver enzymes (aspartate 
transaminase [AST], alanine aminotransferase [ALT]), and albumin concentrations, and 
platelet counts measured as part of the NHANES protocol were included in this cross-
sectional analysis.  
Exposures Liver fibrosis was measured using three established, non-invasive fibrosis 
scores: AST to platelet ratio index (APRI), fibrosis 4 index (FIB-4) and NAFLD fibrosis 
score (NFS). 
Main Outcomes and Measures We assessed the overall and race-stratified geometric 
mean PSA concentrations by categories of the liver fibrosis scores using predictive margins 
by multivariable linear regression, and the association of abnormal liver fibrosis scores 
(APRI>1, FIB-4 >2.67, NFS>0.676) and elevated PSA levels (>2ng/mL, >4ng/mL) by 
multivariable logistic regression. We adjusted for age, race/ethnicity, body mass index, 
diabetes status, alcohol drinking, and smoking. 
Results Overall, 6,774 men were included in this study (mean age 55.1 years). Men with 
higher liver fibrosis scores had lower geometric mean PSA: APRI (p trend<0.001), FIB-4 
(p trend=0.007) and NFS (p trend<0.001). After stratifying by race, this pattern remained 
among each race/ethnicity, though not statistically significant among non-Hispanic Black 
and Mexican-American/Other Hispanic men (both p trend>0.05). Men with abnormal liver 
fibrosis scores had a lower PSA compared with those without advanced liver fibrosis, 
which was also observed in each race/ethnicity group p <0.05). Moreover, regardless of 
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the race/ethnicity men with abnormal liver fibrosis scores had a lower odds of an elevated 
PSA level (e.g., defined by APRI: OR of PSA >2 ng/mL=0.67; OR of PSA >4 ng/mL=0.33). 
Conclusions and Relevance In this US nationally representative study, men of all 
race/ethnicities with higher liver fibrosis scores had lower serum PSA concentration and 
men with advanced fibrosis scores had a lower odds of an elevated PSA, which could lower 
the probability of detecting asymptomatic prostate cancer. Given that early detection may 
be beneficial for prostate cancer treatment and survival and given that Black men are more 
likely to develop aggressive prostate cancer, a delayed diagnosis could contribute to the 
higher prostate cancer mortality among US Black men. As for any man, the risk and 
benefits of prostate cancer screening for men with diagnosed liver disease should be 
considered in decision-making.  
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Evidence from studies of cirrhotic patients links poor liver function to a reduction in serum 
prostate-specific antigen (PSA) concentration among men.1-3 The liver plays a key role in 
both PSA production and clearance.4 Reduced PSA clearance by an impaired liver could 
result in a higher serum PSA concentration. On the other hand, with chronic poor liver 
function, testosterone levels drop, which can result in a decline in the production of PSA, 
which is under androgenic regulation.5,6 The usual PSA concentration for which biopsy is 
indicated is at >4 ng/mL. A shift in the distribution of PSA concentration toward a higher 
level could result in some men without prostate cancer being sent for an unnecessary biopsy. 
Alternatively, a shift in the distribution of PSA concentration toward lower levels could 
result in some men with yet undiagnosed prostate cancer from being detected with the 
disease while it is still asymptomatic. Moreover, the majority of PSA circulates bound to 
several proteins (alpha 1-antitrypsin, alpha 1-antichymotrypsin and alpha 2-
macroglobulin); these proteins are synthesized by the liver.  
Over the last 2 decades, PSA testing has been adopted for prostate cancer early detection 
throughout the US.7 Lower PSA concentration at the time of screening may lead to a delay 
in detection of prostate cancer with a lethal phenotype. Black men experience profound 
disparity in metastatic and lethal prostate cancer rates compared with White men in the 
US.8,9 According to the most recent statistics from American Cancer Society, the incidence 
of prostate cancer is 198.4 per 100,000 among non-Hispanic Black men, 114.8 per 100,000 
among non-Hispanic White men, and 104.9 per 100,000 among the Hispanic/Latino men; 
the non-Hispanic Black men have a more than twice higher risk of dying from this disease 
than their White or Hispanic/Latino counterparts.10 Meanwhile, previous studies in the US 
nationally representative National Health and Nutrition Examination Survey (NHANES) 
document that a racial disparity in certain types of liver diseases. For example, non-
Hispanic Blacks had a higher prevalence of cirrhosis and infectious hepatitis 11-13, while 
nonalcoholic fatty liver disease (NAFLD) was more common in Mexican American. 14 The 
higher burden of liver diseases in certain subgroups, may help explain the racial disparities 
observed in the incidence of metastatic and lethal prostate cancer. Given that early 
detection may be beneficial for prostate cancer treatment and survival, a delayed diagnosis 
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of aggressive prostate cancer could contribute to the higher prostate cancer mortality 
among Black American men.15 
Thus, in this study we determined the association between liver fibrosis scores and serum 
PSA concentration overall and by race/ethnicity in a nationally representative sample of 
men in the target age range for prostate cancer screening. We address this question to 
inform the likelihood of delay in the detection of prostate cancer in men with liver 
conditions and also whether the higher risk of prostate cancer death in Black men may be, 
in part, due to a higher prevalence of liver fibrosis and consequent influence on the tool 






We used data from five cycles of Continuous NHANES (2001-2002, 2003-2004, 2005-
2006, 2007-2008 and 2009-2010). NHANES is a US nationally representative survey that 
aims to provide knowledge on the health status of US population through collecting data 
from interviews, physical examinations, and laboratory measurements. The survey used a 
complex, multistage, probability design to select a study sample from the civilian, 
noninstitutionalized population with oversampling of non-Hispanic Blacks, Asians, 
Hispanic Americans, and persons aged 60 years or older. Use of sampling weights 
produces nationally representative estimates. Detailed study design, content, and 
procedures have been discussed in previous reports.16 Written informed consents were 
obtained from all participants, and all protocols of NHANES studies implementation were 
under approval by the Research Ethics Review Board of the National Center for Health 
Statistics, US Centers for Disease Control and Prevention.  
In our study, we restricted our analyses to male participants 40 years or older given that 
serum PSA levels were only measured among them. In addition, we excluded those with 
missing data on demographics (age and ethnicity) and clinical data (liver fibrosis scores 
biomarkers, body mass index (BMI), diabetes status, smoking, and alcohol drinking history, 
viral hepatitis). We further excluded from the analysis males with extreme BMI (<18.5 
or >50 kg/m2), with self-reported liver transplant, prostate cancer or liver cancer. The total 
analytical and unweighted sample size was n=6,705.  
Measurement of PSA 
As part of the NHANES protocol, from 2001 to 2010, serum total PSA concentration was 
measured by Hybritech immunoassay (Beckman Coulter, Fullerton, CA) for male 
participants aged 40 years and over 17. PSA was not measured for men with a recent 
prostate biopsy, prostate infection or inflammation, rectal examination, or for men with a 
history of prostate cancer.  
Assessment of liver fibrosis 
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As part of the NHANES protocol, biochemical markers related to liver function – aspartate 
aminotransferase (AST), alanine aminotransferase (ALT) – as well as albumin were 
measured using a Beckman Synchron LX20. In addition, platelet count was measured using 
the Beckman UniCel® DxC800 Synchron; detailed procedures are described elsewhere.17 
To assess liver fibrosis of participants, we estimated three non-invasive fibrosis scores: 
AST/platelet ratio index (APRI), fibrosis 4 index (FIB-4) and NAFLD fibrosis score (NFS). 
The APRI and FIB-4 indices were originally developed to predict fibrosis and cirrhosis 
among patients with hepatitis C18,19 and have been validated in other chronic liver diseases 
in later studies to accurately identify patients with significant fibrosis.20-23 Given its 
simplicity and validity, APRI is recommended by the World Health Organization to 
identify fibrosis stage in resource-constrained areas.24 The NFS was developed to identify 
advanced fibrosis in patients with NAFLD and showed 0.84 of the area under the ROC 
curve.25 The scores were calculated by following equations: 
APRI = ((AST [U/L] / upper limit of normal) / platelet count [109/L]) ×100                      (1) 
FIB-4 = (Age [yrs] × AST [U/L]) / (platelet count [109/L] × ALT [U/L]1/2)                      (2) 
NFS = −1.675 + (0.037 × age [yrs]) + (0.094 × BMI [kg/m2]) + (1.13 × impaired fasting 
glucose or diabetes) + (0.99 × AST/ALT) - (0.013 × platelet count [109/L]) - (0.66 × 
albumin (g/dL))                                                                                                                                 (3) 
In the formula above, BMI was calculated as weight (kg) divided by height (m) squared. 
Participant were defined as having impaired fasting glucose or a diagnosis of diabetes when 
their fasting glucose was >100 mg/dL or they responded yes to the question of whether a 
“Doctor told you have diabetes”. 26 We used 33 U/L as upper-limit of normal of AST based 
on published NHANES ranges. 27 In our study, we defined abnormal fibrosis score as: 
APRI>1, FIB-4 >2.67 or NFS>0.676.28,29 
Other covariates 
As part of NHANES, information regarding age at survey, race/ethnicity, education level, 
drinking status, smoking history were collected by questionnaire. We categorized 
race/ethnicity was categorized as “Non-Hispanic White”, “Non-Hispanic Black”, 
“Mexican American or other Hispanic” and “other race”. Participants’ highest achieved 
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education level was classified into 5 groups: “less than 9th grade”, “9-11th grade (includes 
12th grade with no diploma)”, “high school graduate/GED or equivalent”, “some college 
or associate’s degree” and “college graduate or above”. Drinking status was estimated 
through the participants’ self-reported average daily alcohol consumption and drinking 
frequency. Males who consumed ≥30 g alcohol per day were categorized as “heavy 
drinker”, otherwise they were categorized as “non-heavy drinker”. Men who reported 
current smoking or previous consumption of at least 100 cigarettes were categorized as 
“positive smoking history”, otherwise they were categorized as “negative smoking history”.  
Using the CDC standard, men with a BMI ≥30 kg/m2 were classified as “obese”30, 
otherwise, they were classified as “normal/overweight”. We classified men with respect to 
diabetes status and glycemia control: men who did not report a diagnosis of diabetes and 
had glycated hemoglobin <5.7% were classified as “no diabetes”; men who did not report 
a diagnosis of diabetes and had a glycated hemoglobin of 5.7%-6.4% were classified as “at 
risk for diabetes”; men who reported a diagnosis of diabetes and had a glycated hemoglobin 
of <7% were classified as “controlled diabetes”; men with a diagnosis of diabetes and who 
had a glycated hemoglobin ≥7% or men without a diagnosis of diabetes but who had a 
glycated hemoglobin >6.4% were classified as “uncontrolled diabetes”.31  
Self-reported liver disease was obtained through the question “Has a doctor or other health 
professional ever told you had any kind of liver condition?” Liver condition included viral 
hepatitis, NAFLD, liver cancer, etc. Hepatitis B and C testing were performed and among 
NHANES participants. We considered participants with positive result of hepatitis C 
antibody (anti-HCV) test as HCV infected.  Participants tested positive for hepatitis B core 
antibody (anti-HBc) were considered as with current or previous HBV infection and those 
tested positive for hepatitis B surface antigen (HBsAg) were considered as with chronic 
HBV infection. HBsAg was only tested if one showed positive in Anti-HBc. The laboratory 
process of has been discussed elsewhere. 13,32  
Statistical analysis 
To account for the clustered design and differential sampling probabilities, sample weights 
that reflect the probability of selection and response were used in the analysis to produce 
unbiased national estimates and the Taylor linearization method and the masked variance 
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units (MVU) were used for variance estimation to account for the complex NHANES 
sample design. Participant characteristics were compared by normal/abnormal fibrosis 
score and by PSA level (<1, 1- 2, 2-4, 4-10, ≥10 ng/mL); PSA> 4ng/mL is the typically 
clinical cut-point for referring to prostate biopsy. 
The PSA concentration was transformed using the natural logarithm to achieve a normal 
distribution for further analyses. Overall and race-stratified geometric mean PSA 
concentration and 95% confidence intervals (CIs) were estimated using predictive margins 
(model-based standardization) from multivariable linear regression. In the regression 
models, we entered quintiles of each fibrosis score or clinical categories (normal vs. 
abnormal). P-trends were estimated using linear regression with the median of each fibrosis 
score category as continuous variable to capture the direction of the association between 
liver function score and PSA concentration. Logistic regression was used to estimate the 
odds ratio (OR) of higher PSA level (>2, >4, or >10 ng/mL) associated with abnormal liver 
fibrosis scores. 
We also conducted sensitivity analyses by restricting to males with BMI <30 kg/m2, males 
without a diagnosis of diabetes or a glycated hemoglobin >6.4%, males with self-reported 
liver disease, males with self-reported liver disease and/or current or previous viral 
hepatitis, and males with self-reported liver disease and/or chronic viral hepatitis 
respectively. We re-classified abnormal/normal fibrosis score by creating an indicator of 
the number of abnormal APRI, FIB-4 and NFS scores, and analyzed the association 
between the joint indicator and elevated PSA concentration through logistic regression.  
All p-values were 2 tailed and p<0.05 was used as the threshold for statistical significance. 
All statistical analyses were carried out using STATA 14.2 for Windows statistical 




Study Population Characteristics 
Table 1 compares weighted general characteristics by fibrosis scores. Based on different 
fibrosis scores, 2.1% males had abnormal APRI score, 3.6% males had abnormal FIB-4 
score, and 5.6% males had abnormal NFS score. The proportions slightly differed by race 
(proportions of abnormal fibrosis score defined by APRI, FIB-4 and NFS: 1.8%, 3.6% and 
5.8% in non-Hispanic Whites; 3.5%, 4.5% and 5.4% in non-Hispanic Blacks; 2.8%, 2.7% 
and 3.9% in Mexican American/other Hispanics). The mean age of the overall participants 
was 55.1 years. In general, the men with abnormal score tended to be older, to be non-
Hispanic White, to have a lower educational level, to be heavy drinkers, to have ever 
smoked, to be obese, to have diabetes or prediabetes, to have self-reported liver disease, 
and to have HCV or HBV infection. In Table 2, we examined the general characteristics of 
the men by categories of PSA concentration. PSA levels increased with age, and as serum 
PSA concentration increased, the proportion of men who are non-Hispanic Black, who 
have a lower educational level, or who were current or previous HBV infected increased, 
while the proportion of men with obesity, with self-reported liver disease, or with HCV 
infection decreased. 
Liver fibrosis scores and geometric mean PSA 
The figures show the age-adjusted association between fibrosis scores and geometric mean 
PSA concentration. Geometric mean PSA decreased with increasing APRI, FIB-4, and 
NFS scores (Figure 1.A-C). After dividing fibrosis scores into quintiles (Table 3), age-
adjusted geometric mean PSA significantly decreased across APRI, FIB-4 and NFS 
quintiles (p trend < 0.001). This trend was consistent after multivariable adjustment. 
Similar trends were also observed in the sensitivity analysis among males with BMI <30 
kg/m2 and among males without a diagnosis of diabetes or an elevated glycated hemoglobin, 
respectively (Supplement Table 1 and 2). 
After stratifying by race, geometric mean PSA decreased more steeply with increasing 
fibrosis scores in non-Hispanic Whites than in non-Hispanic Blacks and in Mexican-
Americans/other Hispanics (Figure 1.D-F). The trends among each race became more 
consistent after excluding the influential points (Supplement Figure 1. D-F). After dividing 
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fibrosis scores into quintiles, all three fibrosis scores were inversely associated with PSA 
concentration among non-Hispanic Whites and among Mexican-American/other Hispanics, 
whereas among non-Hispanic Blacks, fibrosis scores were not associated with PSA 
concentration (Table 4).  
After restricting to men who reported a diagnosis of liver disease, geometric mean PSA 
decreased with increasing fibrosis scores in each racial/ethnic group (Figure 2). After 
dividing fibrosis scores into quintiles, geometric mean PSA decreased across quintiles of 
fibrosis scores overall and this pattern was observed in each racial/ethnic group; the trend 
was statistically significant after multivariable adjustment among non-Hispanic Whites and 
non-Hispanic Blacks (both p trends < 0.05; Supplement Table 3). In the sensitivity analyses 
we restricted to men with self-reported liver disease and/or viral hepatitis infection 
confirmed by serum test, there was a decreasing trend of geometric mean PSA with 
increasing fibrosis scores among the White men, but no association among Black men or 
Mexican American/other Hispanics (Supplement Table 4, Supplement Figure 2 and 3). 
We also determined geometric mean PSA concentration within clinical categories of the 
fibrosis scores (Table 5). Regardless the score, males with abnormal scores suggestive of 
advanced fibrosis have significantly lower level of geometric mean serum PSA (range of 
difference: 0.15-0.21ng/mL). This pattern was also observed after multivariable adjustment, 
and was observed in each race/ethnicity across all three scores.   
Liver fibrosis scores and elevated serum PSA concentration 
Lastly, we examined the association between liver fibrosis scores and the odds of having 
elevated PSA, we selected 2 cut points which are often used as indication for prostate 
biopsy (Table 6).  Overall, after multivariable adjustment, the odds ratios (OR) of elevated 
PSA for abnormal fibrosis score defined by APRI was 0.67 (95% CI: 0.39, 1.16) for 
PSA >2 ng/mL and 0.33 (95% CI: 0.11, 0.96)  for PSA >4 ng/mL, for those with elevated 
FIB-4 the corresponding OR(95% CI) were 0.64(0.45, 0.92) and 0.67(0.44, 1.03), and for 
those with elevated NFS were 0.76(0.59, 0.98) and 0.71(0.50, 1.00) . After stratifying by 
race, similar trends were observed but did not reach statistical significance among each 
race/ethnicity group. For FIB-4 and NFS, men who had an abnormal score were less likely 
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to have a PSA >10 ng/mL, albeit 95% CIs were wide (data not shown); the analysis was 
too sparse for APRI. 
To improve classification of abnormal and normal liver fibrosis scores, we classified the 
men by the number of the three abnormal APRI, FIB-4 and NFS fibrosis scores (0, 1, or 2 
or 3 abnormal fibrosis scores). As shown in supplemental table 5, overall, compared with 
men with 0 abnormal scores, those with 1 abnormal and those with 2 or 3 abnormal fibrosis 
scores had a lower odds of PSA >2 ng/mL (OR: 0.83 and 0.59), PSA >4 ng/mL (OR: 0.80 
and 0.55), and PSA > 10 ng/mL (OR: 0.76 and 0.45). After stratifying by race/ethnicity, 
the association between number of abnormal fibrosis scores and elevated PSA among each 
race/ethnicity was inverse as for overall, although was less strong among non-Hispanic 





In this US nationally representative study of men without a prostate cancer diagnosis, we 
found that men with higher liver fibrosis scores had lower serum PSA concentration. This 
association was consistent among individuals without obesity and also those without 
diabetes. Furthermore, the results were similar across race/ethnic groups. Given the 
increasing prevalence of liver fibrosis, as a result of the rising occurrence of nonalcoholic 
fatty liver disease, our findings have important implications for early detection of prostate 
cancer, especially in Black men who tend to have more aggressive prostate cancer.  
To date, no consensus has been reached regarding the impact of liver function on PSA 
concentration. To our knowledge, our study is the first to examine this association among 
men aged older than 40 years in the overall US population, and the results are consistent 
with previous studies observing that serum PSA tended to be lower in men with cirrhosis 
than men without cirrhosis.1,2,5,33,34 With respect to liver function, a study of 38,157 healthy 
Korean males also found that men with a higher serum concentration of the liver enzyme 
ALT had a lower PSA concentration.6 Additionally, a small number of studies conducted 
in the US found that PSA concentration was lower among patients with liver diseases than 
in men with normal function, although these findings were based on fewer cases and were 
not statistically significant. 35-37  
Over the last 25 years, testing for elevated PSA has been widely used for the early detection 
of prostate cancer in the US.7 More recently, uptake has decreased due to changing 
screening recommendations from the US Preventive Services Task Force (USPSTF) in 
2012.38-40 However, the early detection of prostate cancer by PSA testing coupled with 
appropriate treatment can reduce the risk of death for a subset of men with lethal type 
prostate cancer.41 For men with liver fibrosis and consequent falsely lower PSA 
concentration could delay their detection and treatment of lethal type prostate cancer, 
possibly increasing risk of death from this cancer. Draft PSA-based prostate cancer 
screening guidelines released by the USPSTF in 2017 indicate that providers should 
discuss the benefits and risk of this test for each patient.40 Whether liver disease should be 
a component of that discussion and also considered in the interpretation of the PSA results 
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remains to be determined, as does how reduced life expectancy due to liver disease affects 
the benefit to risk ratio for screening. 
In this nationally representative study, we also found that the association between liver 
fibrosis score and PSA level across each of the US race/ethnic groups studied. Compared 
with White men, Black men have a significantly higher incidence of prostate cancer, are 
more likely to develop prostate cancer at younger ages, and are more likely to die of 
prostate cancer. 10 Although the racial disparities are not consistent across liver diseases 
(i.e. African American has higher risk of infectious hepatitis, while Mexican American has 
higher risk of NAFLD)13,14, in our study population, the proportion of males with abnormal 
liver fibrosis score was higher among African American than among non-Hispanic Whites 
or Mexican Americans. Given the results of our study, men with presumed liver fibrosis 
were less likely to have PSA >4 ng/mL and would not be referred to prostate biopsy. 
Moreover, among patients with self-repoted liver condition, the PSA concentration among 
non-Hispanic Blacks tended to decrease faster with per unit increase of fibrosis score 
compared with males of other race groups. Therefore, African-American men may be more 
likely to have delayed detection of prostate cancer attributable to a higher prevalence of 
liver fibrosis and a higher risk of prostate cancer than their non-Hispanic White or Mexican 
American counterparts. 
In our analysis restricted to people with diagnosed liver diseases, the association between 
liver fibrosis scores and PSA concentration was even stronger than that in the overall study 
population, especially among non-Hispanic Black and Mexican American/other Hispanic 
men; that is, patients with liver disease are even more likely to have reduced serum PSA 
concentration if they have severe liver fibrosis. Whether men with liver disease and severe 
fibrosis would benefit from prostate cancer screening given the likelihood of reduced life 
expectancy is beyond the scope of this manuscript and future studies are needed to 
determine if this is the case.  
The strengths of our study include that we used a nationally representative sample of men 
in the age range often targeted for the early detection of prostate cancer. Measurements of 
liver enzymes and PSA were not performed for clinical indication and the men were not 
enriched for liver disease. Instead, these measurements were performed on all eligible men 
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as part of the NHANES protocol to understand the health and nutritional status of 
Americans. Thus, the findings are likely generalizable to the US men in these age ranges. 
Secondly, each biomarker was measured under the same protocol in the same laboratory. 
Moreover, this is the first and largest study to examine the association between liver 
fibrosis and PSA in different races/ethnicities.  
One possible limitation of our study is that we used non-invasive indicators to define liver 
fibrosis, which may result in misclassification compared with imaging and the gold 
standard liver biopsy. We used three fibrosis scores that were primarily developed for 
different liver conditions but that have been validated in different populations. 23,28Given 
that each is purported to measure liver fibrosis, we performed a sensitivity analysis in 
which cross-categorized the men with respect to all three of the scores. In doing so, we 
expected that men who truly had liver fibrosis would be more likely score high on two or 
three of these scores, while those who truly did not have liver fibrosis would be more likely 
to score low on all three of these scores. The results (i.e., lower PSA in those most likely 
to have liver fibrosis than in those unlikely to have liver fibrosis) when using the cross-
classification categories were consistent with those when using the three scores separately.  
Another limitation of the current study is that it was cross-sectional, and we are not able to 
evaluate how progression to fibrosis influences PSA concentration. We were not able to 
study the mechanism by which liver fibrosis influences the detectable level of PSA in 
circulation. We had initially hypothesized that liver fibrosis  would be associated with 
higher serum PSA because the liver is the primary site for PSA metabolism and 
clearance.4,42 However, we also recognized that men with liver cirrhosis have substantially 
lower testosterone levels,43 and given that PSA is under androgenic regulation,44 we 
alternatively hypothesized that men with fibrosis  may have lower serum PSA due to their 
reduced testosterone level.  
We cannot rule out that the inverse association that we observed between liver fibrosis 
scores and PSA is explained by men with abnormal liver function being less likely to 
develop prostate cancer, and thus have lower serum PSA levels. As prostate growth is 
dependent on androgens, levels of which can be influenced by hepatic function, liver 
disease may impact the risk of prostate cancer.44,45 To address this alternative explanation 
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for our findings, a prospective study of men with and without liver disease followed for a 
decade or more for the development of clinically-detectable prostate cancer or for prostate 
cancer detected by biopsy performed irrespective of PSA level would be needed. Such a 
study is unlikely to be conducted in the future. Nevertheless, irrespective of the mechanism 
by which poor liver function may affect serum PSA and the development of prostate cancer 
(and associated PSA level), it may serve as a patient characteristic that could be considered 
in the discussion on PSA-based prostate cancer screening and possibly in the interpretation 
of the PSA value.  
In conclusion, men with an abnormal liver fibrosis score may be less likely to have an 
elevated PSA. Lower PSA could results in a higher probability of delayed detection of 
prostate cancer, including disease with a lethal phenotype, including in Black men who are 
more likely to have aggressive prostate cancer and die of this cancer. 
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APPENDIX 
Table 1. Characteristics by Liver Fibrosis Scores Among Men 40 Years and Older, NHANES 2001-2010 
 Overall APRI FIB-4 NFS 
 
 Normal Abnormala Normal Abnormal Normal Abnormal 
Unweighted Participants 6,705 6,541 164 6,319 386 6,139 566 
Mean age at survey, years (standard error) 55.1(0.2) 55.1(0.2) 54.5(0.9) 54.6(0.2) 68.3(0.8) 54.3(0.2) 68.8(0.5) 
Race/ethnicity, % (95% Confidence 
Interval)         




























































Education level, % (95% Confidence 
Interval)        












































































Drinking status, % (95% Confidence 
Interval)        































Smoking history, % (95% Confidence 
Interval)        






























BMI category, % (95% Confidence 
Interval)          





























Diabetes status, %  
(95% Confidence Interval)          




























































Self-reported liver disease, % (95% 
Confidence Interval)        






























HCV status, % (95% Confidence Interval)        






























HBV status, % (95% Confidence Interval)        















  Current or previous HBV infected 7.8 7.6 20.8 7.6 14.4 7.7 9.9 
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(7.0-8.8) (6.7-8.5) (13.9-30.0) (6.7-8.6) (10.1-20.2) (6.8-8.7) (7.3-13.4) 




















Table 2. Characteristics by PSA Level Among Men 40 Years and Older, NHANES 2001-2010 
 PSA serum concentration (ng/mL) 
 <1 1 to <2 2 to <4 4 to <10 ≥10 
Unweighted Participants 3,338 1,809 961 482 115 
Mean age at survey, years (standard error) 52.1(0.2) 55.7(0.3) 61.5(0.4) 66.8(0.6) 69.0(1.9) 
Race/ethnicity, % (95% Confidence Interval)        












































Education level, % (95% Confidence Interval)        























































Drinking status, % (95% Confidence Interval)      






















Smoking history, % (95% Confidence Interval)      






















BMI category, % (95% Confidence Interval)      
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Diabetes status, % (95% Confidence Interval)        












































Self-reported liver disease, % (95% Confidence 
Interval) 
     






















HCV status, % (95% Confidence Interval)      





















HBV status, % (95% Confidence Interval)      


































Table 3. Geometric Mean Serum PSA Concentration (ng/mL) and 95% Confidence Intervals by Quintile of Fibrosis Scores Among Men 40 Years 
and Older, NHANES 2001-2010 
 APRI  
 Q1 (<0.24) Q2 (0.24 to <0.29) Q3 (0.29 to <0.35) Q4 (0.35 to <0.44) Q5 (≥0.44) 
Per 1 unit increase in 
fibrosis score  
(p trend) 
Model 1a  1.03 (0.98,1.09) 0.96 (0.91,1.02) 0.94 (0.89,0.99) 0.97 (0.93,1.01) 0.89 (0.84,0.95) -0.36 (<0.001) 
Model 2b 1.04 (0.99,1.10) 0.96 (0.91,1.02) 0.93 (0.89,0.98) 0.97 (0.93,1.01) 0.89 (0.84,0.95) -0.38 (<0.001) 
 FIB4  
 Q1 (<0.79) Q2 (0.79 to <0.99) Q3 (0.99 to <1.23) Q4 (1.23 to <1.62) Q5 (≥1.62) 
Per 1 unit increase in 
fibrosis score  
 (p trend) 
Model 1  1.03 (0.97,1.08) 0.96 (0.92,1.01) 0.97 (0.91,1.03) 0.94 (0.89,0.99) 0.90 (0.84,0.96) -0.09 (0.007) 
Model 2  1.04 (0.99,1.10) 0.97 (0.93,1.02) 0.97 (0.92,1.03) 0.94 (0.89,0.99) 0.88 (0.83,0.95) -0.11 (0.001) 
 NFS  
 Q1 (<0.17) Q2 (0.17 to <0.89) Q3 (0.89 to <1.58) Q4 (1.58 to <2.42) Q5 (≥2.42) 
Per 1 unit increase in 
fibrosis score  
 (p trend) 
Model 1  1.05 (1.00,1.11) 0.99 (0.94,1.04) 1.01 (0.96,1.05) 0.92 (0.86,0.98) 0.84 (0.78,0.91) -0.06 (<0.001) 
Model 2  1.02 (0.96,1.08) 0.96 (0.92,1.01) 1.00 (0.95,1.04) 0.93 (0.87,0.99) 0.89 (0.82,0.96) -0.04 (0.017) 
a Model 1 adjusted for age and race;  
b Model 2 adjusted for the age, race, BMI category, diabetes status, alcohol drinking status and smoking status. 
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Table 4. Association Between Fibrosis Score and Natural Logarithm Transformed Serum PSA Concentration (ng/mL) by Race/Ethnicity Among 
Men 40 Years and Older, NHANES 2001-2010 
 White (non-Hispanic) Black (non-Hispanic) Mexican-American/Other Hispanic 
 APRI 
 Per 1 unit increase in fibrosis 
score 
p trend 
Per 1 unit increase in fibrosis 
score 
p trend 
Per 1 unit increase in fibrosis 
score 
p trend 
Model 1a -0.40 <0.001 -0.03 0.89 -0.32 0.073 
Model 2b -0.41 <0.001 -0.01 0.66 -0.34 0.065 
 FIB4 
 Per 1 unit increase in fibrosis 
score 
p trend 
Per 1 unit increase in fibrosis 
score 
p trend 
Per 1 unit increase in fibrosis 
score 
p trend 
Model 1 -0.09 0.039 0.00 0.96 -0.14 0.020 
Model 2 -0.11 0.012 -0.03 0.66 -0.15 0.016 
 NFS 
 Per 1 unit increase in fibrosis 
score 
p trend 
Per 1 unit increase in fibrosis 
score 
p trend 
Per 1 unit increase in fibrosis 
score 
p trend 
Model 1 -0.06 <0.001 -0.01 0.68 -0.04 0.083 
Model 2 -0.04 0.051 0.01 0.82 -0.03 0.37 
a Model 1 adjusted for age and race;  




Table 5.  Geometric Mean Serum PSA Concentration (ng/mL) and 95% Confidence Intervals by Abnormal versus Normal Fibrosis Scores Overall 
and By Race/Ethnicity Among Men 40 Years and Older, NHANES 2001-2010 




 Normal Abnormalc Normal Abnormal Normal Abnormal Normal Abnormal 
Model 1a  0.96 0.75 0.97 0.69 1.00 0.86 0.95 0.89 
 (0.94,0.99) (0.64,0.88) (0.94,1.00) (0.55,0.86) (0.95,1.06) (0.66,1.12) (0.89,1.01) (0.72,1.09) 
Model 2b 0.96 0.76 0.97 0.71 1.00 0.82 0.95 0.9 
 (0.94,0.99) (0.64,0.89) (0.94,1.00) (0.57,0.89) (0.95,1.07) (0.63,1.07) (0.89,1.01) (0.72,1.13) 
 FIB4 
 Normal Abnormal Normal Abnormal Normal Abnormal Normal Abnormal 
Model 1  0.96 0.81 0.97 0.79 1.00 0.92 0.95 0.88 
 (0.94,0.99) (0.70,0.93) (0.94,1.00) (0.66,0.95) (0.94,1.06) (0.72,1.18) (0.89,1.01) (0.67,1.15) 
Model 2  0.96 0.80 0.97 0.79 1.00 0.89 0.95 0.88 
 (0.94,0.99) (0.70,0.93) (0.94,1.00) (0.66,0.95) (0.95,1.06) (0.69,1.13) (0.89,1.01) (0.66,1.17) 
 NFS 
 Normal Abnormal Normal Abnormal Normal Abnormal Normal Abnormal 
Model 1  0.97 0.77 0.97 0.78 1.00 0.98 0.95 0.82 
 (0.95,1.00) (0.71,0.84) (0.94,1.00) (0.71,0.86) (0.94,1.06) (0.79,1.22) (0.89,1.01) (0.66,1.01) 
Model 2 0.97 0.83 0.97 0.85 1.00 1.02 0.95 0.84 
 (0.94,0.99) (0.77,0.90) (0.94,1.00) (0.77,0.94) (0.94,1.06) (0.81,1.29) (0.89,1.01) (0.69,1.04) 
a Model 1 adjusted for age and race, numbers with bold font implies p<0.05;  
b Model 2 adjusted for the age, race, BMI category, diabetes status, alcohol drinking status and smoking status; 








Table 6.  Association between Abnormal Fibrosis Score and Elevated Serum PSA Concentration Overall and by Race/Ethnicity Among Men 40 
Years and Older, NHANES 2001-2010 
PSA concentration (ng/mL) 
Odds Ratio (95% Confidence Interval) a 




>2 0.67 (0.39,1.16) 0.58 (0.28,1.22) 0.99 (0.35,2.85) 0.83 (0.30,2.33) 
>4 0.33 (0.11,0.96) 0.26 (0.06,1.21) 0.19 (0.02,1.70) 0.28 (0.03,2.22) 
 FIB4 
>2 0.64 (0.45,0.92) 0.59 (0.38,0.92) 1.24 (0.61,2.53) 0.95 (0.42,2.15) 
>4 0.67 (0.44,1.03) 0.69 (0.42,1.12) 0.59 (0.27,1.28) 0.66 (0.24,1.82) 
 NFS 
>2 0.76 (0.59,0.98) 0.75 (0.56,1.01) 0.88 (0.50,1.57) 1.08 (0.59,1.97) 
>4 0.71 (0.50,1.00) 0.70 (0.47,1.04) 0.55 (0.24,1.27) 0.83 (0.34,2.02) 
a Adjusted for the age, BMI category, diabetes status, alcohol drinking status and smoking status. 
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Supplement Table 1. Association Between Fibrosis Score and Natural Logarithm Transformed Serum PSA Concentration (ng/mL) by Race/Ethnicity 
Among Men 40 Years and Older and With BMI <30 kg/m2, NHANES 2001-2010 (unweighted N = 4,458) 





















Model 1a -0.24 0.051 -0.30 0.047 -0.02 0.93 -0.08 0.72 
Model 2b -0.28 0.030 -0.34 0.030 -0.09 0.75 -0.09 0.69 
 FIB4 
 
















Model 1 -0.08 0.060 -0.09 0.096 0.04 0.63 -0.10 0.19 
Model 2 -0.09 0.048 -0.10 0.081 0.02 0.84 -0.11 0.14 
 NFS 
 
















Model 1 -0.05 0.022 -0.05 0.053 0.01 0.87 -0.04 0.13 
Model 2 -0.04 0.084 -0.04 0.16 0.02 0.67 -0.03 0.29 
a Model 1 adjusted for age and race;  




Supplement Table 2. Association Between Fibrosis Score and Natural Logarithm Transformed Serum PSA Concentration (ng/mL) by Race/Ethnicity 
Among Men 40 Years and Older and Without a Diagnosis of Diabetes or an Elevated Glycated Hemoglobin, NHANES 2001-2010 (unweighted N = 
3,656) 





















Model 1a -0.27 0.017 -0.28 0.047 0.01 0.97 -0.44 0.091 
Model 2b -0.30 0.012 -0.32 0.029 -0.03 0.91 -0.46 0.077 
 FIB4 
 
















Model 1 -0.08 0.050 -0.07 0.15 0.00 0.97 -0.2 0.012 
Model 2 -0.09 0.026 -0.09 0.083 -0.02 0.80 -0.21 0.020 
 NFS 
 
















Model 1 -0.03 0.13 -0.02 0.24 0.01 0.68 -0.02 0.66 
Model 2 -0.03 0.18 -0.02 0.29 0.02 0.65 -0.04 0.43 
a Model 1 adjusted for age and race;  
b Model 2 adjusted for the age, race, BMI category, , alcohol drinking status and smoking status. 
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Supplement Table 3. Association Between Fibrosis Score and Natural Logarithm Transformed Serum PSA Concentration (ng/mL) by Race/Ethnicity 
Among Men 40 Years and Older and With Self-reported Liver Disease, NHANES 2001-2010 (unweighted N = 288) 





















Model 1a -1.03 0.008 -1.14 0.019 -1.27 0.23 -0.23 0.85 
Model 2b -1.09 0.002 -1.14 0.008 -2.46 0.027 -0.24 0.79 
 FIB4 
 
















Model 1 -0.36 0.009 -0.32 0.058 -0.25 0.51 -0.30 0.15 
Model 2 -0.41 0.003 -0.35 0.031 -0.80 0.042 -0.19 0.44 
 NFS 
 
















Model 1 -0.17 <0.001 -0.16 0.001 -0.42 0.016 -0.24 0.019 
Model 2 -0.15 <0.001 -0.13 0.007 -0.24 0.019 -0.15 0.16 
a Model 1 adjusted for age and race;  




Supplement Table 4. Association Between Fibrosis Score and Natural Logarithm Transformed Serum PSA Concentration (ng/mL) by Race/Ethnicity 
Among Men 40 Years and Older and With Self-reported Liver Disease and/or Current or Previous Viral Hepatitis a, NHANES 2001-2010 
(unweighted N = 935) 





















Model 1b -0.24 0.051 -0.30 0.047 -0.02 0.93 -0.08 0.72 
Model 2c -0.28 0.030 -0.34 0.030 -0.09 0.75 -0.09 0.69 
 FIB4 
 
















Model 1 -0.77 0.002 -0.95 -0.004 0.01 0.97 -0.45 0.52 
Model 2 -0.84 0.001 -1.00 <0.001 -0.14 0.73 -0.31 0.64 
 NFS 
 
















Model 1 -0.16 <0.001 -0.18 <0.001 -0.04 0.46 -0.17 0.021 
Model 2 -0.13 <0.001 -0.14 0.001 -0.01 0.86 -0.11 0.20 
a Current or previous viral Hepatitis was defined as anti-HCV positive or anti-HBc positive; 
b Model 1 adjusted for age and race; 




Supplement Table 5. Association between Joint Indicators of Abnormal APRI, FIB4 and NFS Scores and Elevated Serum PSA Concentration Overall and by 




Odds Ratio (95% Confidence Interval) a for number of Abnormal Liver Fibrosis Scores 
Overall White (non-Hispanic) Black (non-Hispanic) Mexican-American/Other Hispanic 












































































a Adjusted for the age, BMI category, diabetes status, alcohol drinking status and smoking status; 
b 0: without any abnormal fibrosis score;  
c 1: has only one abnormal fibrosis score; 




A.                      
Figure 1. Association between Fibrosis Scores and Geometric Mean PSA Serum Concentration (ng/mL) Overall (Panel A, B, C) and By Race (Panel D, 
E, F) Among Men 40 Years and Older, NHANES 2001-2010  
In the panel A, B and C, the solid line indicates the estimated geometric mean of PSA, while the dash line indicates the 95% Confidence Interval of the estimated 
geometric mean of PSA. The histogram at the upper right corner of each panel displays the density distribution of APRI, FIB-4, and NFS score, respectively. In 
the panel D, E and F, the blue line indicates the estimated geometric mean of PSA among non-Hispanic Whites, the red line indicates non-Hispanic Blacks, and 
the green line indicates Mexican American/other Hispanics. The x-axis ranges represent the true ranges of fibrosis scores among the analyzed population. 
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Figure 2. Association between Fibrosis Scores and Geometric Mean PSA Serum Concentration (ng/mL) Overall (Panel A, B, C) and By Race (Panel D, 
E, F) Among Men 40 Years and Older and With Self-reported Liver Disease, NHANES 2001-2010   
In the panel A, B and C, the solid line indicates the estimated geometric mean of PSA, while the dash line indicates the 95% Confidence Interval of the estimated 
geometric mean of PSA. The histogram at the upper right corner of each panel displays the density distribution of APRI, FIB-4, and NFS score, respectively. In 
the panel D, E and F, the blue line indicates the estimated geometric mean of PSA among non-Hispanic Whites, the red line indicates non-Hispanic Blacks, and 




Supplement Figure 1. Association between Fibrosis Scores and Geometric Mean PSA Serum Concentration (ng/mL) Overall (Panel A, B, C) and By 
Race (Panel D, E, F) Among Men 40 Years and Older after Excluding Influential Points, NHANES 2001-2010  
In the panel A, B and C, the solid line indicates the estimated geometric mean of PSA, while the dash line indicates the 95% Confidence Interval of the estimated 
geometric mean of PSA. The histogram at the upper right corner of each panel displays the density distribution of APRI, FIB-4, and NFS score, respectively. In 
the panel D, E and F, the blue line indicates the estimated geometric mean of PSA among non-Hispanic Whites, the red line indicates non-Hispanic Blacks, and 
the green line indicates Mexican American/other Hispanics. The x-axis ranges represent the true ranges of fibrosis scores among the analyzed population. 
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Supplement Figure 2. Association between Fibrosis Scores and Geometric Mean PSA Serum Concentration (ng/mL) Overall (Panel A, B, C) and By 
Race (Panel D, E, F) Among Men 40 Years and Older and With Self-reported Liver Disease and/or Current or Previous Viral Hepatitis, NHANES 
2001-2010  
In the panel A, B and C, the solid line indicates the estimated geometric mean of PSA, while the dash line indicates the 95% Confidence Interval of the estimated 
geometric mean of PSA. The histogram at the upper right corner of each panel displays the density distribution of APRI, FIB-4, and NFS score, respectively. In 
the panel D, E and F, the blue line indicates the estimated geometric mean of PSA among non-Hispanic Whites, the red line indicates non-Hispanic Blacks, and 
the green line indicates Mexican American/other Hispanics. The x-axis ranges represent the true ranges of fibrosis scores among the analyzed population. Current 
or previous viral hepatitis was defined as anti-HCV positive or anti-HBc positive. 
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Supplement Figure 3. Association between Fibrosis Scores and Geometric Mean PSA Serum Concentration (ng/mL) Overall (Panel A, B, C) and By 
Race (Panel D, E, F) Among Men 40 Years and Older and With Self-reported Liver Disease and/or Chronic Viral Hepatitis, NHANES 2001-2010  
In the panel A, B and C, the solid line indicates the estimated geometric mean of PSA, while the dash line indicates the 95% Confidence Interval of the estimated 
geometric mean of PSA. The histogram at the upper right corner of each panel displays the density distribution of APRI, FIB-4, and NFS score, respectively. In 
the panel D, E and F, the blue line indicates the estimated geometric mean of PSA among non-Hispanic Whites, the red line indicates non-Hispanic Blacks, and 
the green line indicates Mexican American/other Hispanics. The x-axis ranges represent the true ranges of fibrosis scores among the analyzed population. 
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